Praxis Precision Medicines PRAX
NASDAQ PRAX
$373.28 +5.26 (+1.43%)
As of: Aug 26, 2026 · 9:49 AM EDT

Praxis Precision Medicines (PRAX) Preferred Stock Liabilities (2019)

Praxis Precision Medicines (PRAX) posted quarterly Preferred Stock Liabilities of $121.1 million for Q4 2019.

Praxis Precision Medicines (PRAX) Preferred Stock Liabilities (2019) Analysis & Trends

Praxis Precision Medicines' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $121.1 million for Q4 2019.

  • In Q4 2019, Preferred Stock Liabilities changed N/A year-over-year to $121.1 million; the TTM figure through Dec 2019 stood at $121.1 million (changed N/A YoY), while the FY2019 annual figure was $121.1 million, changed N/A from the prior year.
  • Preferred Stock Liabilities for Q4 2019 stood at $121.1 million.
  • The five-year high for Preferred Stock Liabilities was $121.1 million in Q4 2019, with the low at $121.1 million in Q4 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Vertex Pharmaceuticals 139.10 Bn 131.24 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 84.66 Bn 76.67 Bn 3.93 Bn -
3 Argenx Se 64.59 Bn 59.40 Bn 1.37 Bn -
4 Moderna 60.02 Bn 54.88 Bn 52.00 Mn -
5 BeOne Medicines 41.64 Bn 36.55 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.90 Bn 28.59 Bn 992.69 Mn -
7 Royalty Pharma 27.38 Bn 26.55 Bn - -
8 BioNTech SE 27.36 Bn 8.97 Bn 668.28 Mn -
9 Insmed 26.66 Bn 25.50 Bn 358.27 Mn -
10 Praxis Precision Medicines 10.86 Bn 10.10 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2019 121.12 Mn